Since resistance to different types of HER2 drugs is still a major challenge in the management of HER2-positive breast cancer, the potency of new targets, including PD-1/PD-L1 inhibitors that can be used with potential anti-HER2 drugs needs to be explored further. Here, ERBB2 is linked to breast carcinoma.